You have no portfolios at this time, click "Manage portfolios" to create your first portfolio.
After Hours 8.54 (%)
Data as of Jan 26
Day's Range8.363 - 8.77
52 Wk Range7.09 - 11.47
50 Day Moving Avg.8.714
Drug Manufacturers - Specialty & Generic
What does this company do
Supernus Pharmaceuticals Inc., was incorporated in Delaware on March 30, 2005. It is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company markets two epilepsy products, Oxtellar XR and Trokendi XR, and has several proprietary product candidates in clinical development that address the attention deficit hyperactivity disorder market. The Company has a broad portfolio of drug development technologies consisting of six platforms that include the following: Microtrol, Solutrol (matrix delivery platform) and EnSoTrol. In addition to Oxtellar XR and Trokendi XR, the Company's proprietary technologies have been used in the following approved products: Carbatrol, Adderall XR, and Intuniv, marketed by Shire; Equetro, marketed by Validus Pharmaceuticals Inc.; Sanctura XR, marketed by Allergan, Inc.; Oracea, marketed by Galderma Laboratories, L.P.; and Orenitram. Oxtellar XR and Trokendi XR are novel extended release formulations of two well known and approved AEDs, oxcarbazepine and topiramate. The Company's psychiatry portfolio includes three product candidates for the treatment of impulsive aggression in patients with ADHD, ADHD or its coexisting conditions and one product candidate for depression, each of which is designed to bring important advancements in therapy. In addition to regulations in the United States, the Company will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of the product candidates to the extent company choose to clinically evaluate or sell any products outside of the United States.